Cancer Efficacy Evaluation Services | SRI International

Toggle Menu

Cancer Efficacy Evaluation Services

SRI is experienced with PDX models and more than 80 cancer primary cell lines. Our in vitro and in vivo efficacy services include:

In Vitro Assays

  • Proliferation, autophagy, and growth inhibition (tumor and endothelial cells)
  • Apoptosis (tumor and endothelial cells)
  • Cell cycle and apoptosis analysis with flow cytometry
  • Migration and invasion (Matrigel® and fibrin gel)
  • Receptor binding and activity
  • Protease activity with zymogels
  • RNA isolation, PCR, RT-PCR, SuperArray®
  • Target effectiveness on treated tissues with biochemical assays
  • Customized assays
  • Angiogenesis
    • Endothelial proliferation, migration, tube formation
    • Ex ovo chick chorioallantoic membrane assay (CAM)

In Vivo Efficacy Expertise – Xenograft Models

  • Patient-derived (PDX) primary tumor xenograft—orthotopic including: breast, pancreas, prostate, colon, brain, lung, AML
  • Human tumor cell line-derived murine xenograft models—orthotopic and subcutaneous
  • More than 18 human tumor tissue types, and more than 80 cell lines are available, including: breast, cervical, colon, fibrosarcoma, glioblastoma, kidney, leukemia, liver, lung, medulloblastoma, melanoma, myeloma, neuroblastoma, osteo- sarcoma, ovarian, pancreatic, prostate, and tongue squamous carcinoma. Additional commercially available tumor-forming lines upon request.
  • Syngeneic mouse models, including colon carcinoma, melanoma, pancreatic carcinoma
  • Angiogenesis with in vivo  human skin graft model

Related: Xenograft Tumor Model Services

Services in Cell Line Testing and Banking

  • Growth rates under optimized culture conditions
  • IC50s for standard cancer chemotherapeutic agents
  • Viability testing protocols
  • Morphology and other characteristics
  • In vivo tumorigenicity
  • Banking
  • Pathogen testing

Noninvasive Imaging Models

SRI offers a complete set of noninvasive imaging models to meet customer needs.

Irradiation Studies

Because irradiation is a treatment approach for many cancers, researchers seek compounds that selectively enhance a tumor’s irradiation sensitivity, protect healthy tissues, or allow increased doses to the affected areas. To address clients’ needs, SRI’s irradiation facilities include a Pantak HF320  X-ray source and a Mark I-68A 137Cs  gamma emission source. Human xenograft, syngeneic, and in vitro models are compatible with radiation administration and can be used to evaluate compounds as radiosensitizers, radioprotectants, decorporation agents, and for use in combination therapy; and SRI’s scientists work closely with clients to develop novel models and customized studies.

Pathology and Follow-On Studies

  • Histology
  • Immunohistochemistry
  • Fluorescence imaging
  • Cellular hypoxia analysis
  • Circulating tumor cells (CTC)
  • Blood vessel density measurements
  • Biochemical assays for target effectiveness
  • Molecular biology assays for tissue analyses, building molecular probes, developing models, for enzymes, cytokines, other protein targets

Projects

scientist working at a computer

Anti-Angiogenic Molecule Treatment for Multiple Myeloma

SRI has developed a promising new treatment for this cancer of the immune system that affects plasma cells in bone marrow.